SGLT‐2 inhibitors may increase the risk of genital tract infections secondary to their mechanism of action23, 24, 25; however, investigation into these infections (eg urinalysis) may prompt further diagnostic workup and eventual diagnosis of bladder cancers that were present before initiation of SGLT‐2 inhibitor therapy. Here, SLC5A2 is linked to urinary bladder carcinoma.